Exactly what I have been saying...investors and BP are not generally clueless, so what is it about CYDY that makes them sit on the sidelines, while other companies with fewer indications and fewer trials as far along as ours are, are getting SP spikes, buyout offers and/or partnership offers. What are we missing?